% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Wolff:279294,
author = {Wolff, Martin and Unuchek, Dmitry and Zhang, Bo and
Gordeliy, Valentin and Willbold, Dieter and Nagel-Steger,
Luitgard},
title = {{A}myloid β {O}ligomeric {S}pecies {P}resent in the {L}ag
{P}hase of {A}myloid {F}ormation},
journal = {PLoS one},
volume = {10},
number = {5},
issn = {1932-6203},
address = {Lawrence, Kan.},
publisher = {PLoS},
reportid = {FZJ-2015-07309},
pages = {e0127865},
year = {2015},
abstract = {Alzheimer’s disease (AD)-associated amyloid β peptide
(Aβ) is one of the main actors in AD pathogenesis. Aβ is
characterized by its high tendency to self-associate,
leading to the generation of oligomers and amyloid fibrils.
The elucidation of pathways and intermediates is crucial for
the understanding of protein assembly mechanisms in general
and in conjunction with neurodegenerative diseases, e.g.,
for the identification of new therapeutic targets. Our study
focused on Aβ42 and its oligomeric assemblies in the lag
phase of amyloid formation, as studied by sedimentation
velocity (SV) centrifugation. The assembly state of Aβ
during the lag phase, the time required by an Aβ solution
to reach the exponential growth phase of aggregation, was
characterized by a dominant monomer fraction below 1 S and a
population of oligomeric species between 4 and 16 S. From
the oligomer population, two major species close to a 12-mer
and an 18-mer with a globular shape were identified. The
recurrence of these two species at different initial
concentrations and experimental conditions as the smallest
assemblies present in solution supports the existence of
distinct, energetically favored assemblies in solution. The
sizes of the two species suggest an Aβ42 aggregation
pathway that is based on a basic hexameric building block.
The study demonstrates the potential of SV analysis for the
evaluation of protein aggregation pathways.},
cin = {ICS-6 / ICS-1},
ddc = {500},
cid = {I:(DE-Juel1)ICS-6-20110106 / I:(DE-Juel1)ICS-1-20110106},
pnm = {553 - Physical Basis of Diseases (POF3-553)},
pid = {G:(DE-HGF)POF3-553},
typ = {PUB:(DE-HGF)16},
UT = {WOS:000355319400055},
pubmed = {pmid:26024352},
doi = {10.1371/journal.pone.0127865},
url = {https://juser.fz-juelich.de/record/279294},
}